BluePearl Pet Hospital and Ardent logos next to each other.

Canine osteosarcoma treatment study.

Study details:

BluePearl is participating in a new clinical study to evaluate the efficacy of K9-ACV (autologous cancer vaccine) for the treatment of appendicular osteosarcoma (OSA) in dogs. Autologous cancer vaccines are produced from a dog's tumor and are therefore specialized to each individual patient.

Inclusion criteria:

  • Dog is ≥ 1 year of age and greater or equal to 20 kilograms in weight.
  • Dog is in good general health, with the exception of appendicular osteosarcoma, Stage IIB.
  • Dog had cytologic and/or histologic confirmation of appendicular osteosarcoma, Stage IIB.
  • Dog had a vaccine produced from its tumor according to the Outline of Production.

Exclusion criteria:

  • Dog received concurrent or previous therapy (within 30 days) with immune-modulating drugs (e.g., cyclosporine, Apoquel, Cytopoint, prednisone, any chemotherapy, etc.)
  • Dog received NSAIDs less than three days before immunization with the IVP.
  • Dogs have received prior radiation therapy or bisphosphonates for their appendicular osteosarcoma.
  • Dog has any uncontrolled medical condition that is likely to be disruptive to the intent of the study.
  • Dog is known to be pregnant or likely to become pregnant during the study.
  • Dog is lactating or intended for breeding during the study.
  • Dog is participating in another therapeutic study.
  • Dog is not available for the duration of the study.

Locations and contacts:

Duration of study:

Eight months.

Covered costs:

Dogs enrolled will have a significant portion of the surgical amputation costs covered, along with all charges for immunotherapy or chemotherapy-related treatment afterwards.